Kyushu University Academic Staff Educational and Research Activities Database
Researcher information (To researchers) Need Help? How to update
Masahiro Ayano Last modified date:2019.06.14





E-Mail
Phone
092-642-5233
Fax
092-642-5247
Academic Degree
PhD
Country of degree conferring institution (Overseas)
No
Field of Specialization
Rheumatology, Clinical Immunology
Total Priod of education and research career in the foreign country
00years00months
Research
Research Interests
  • Roles of CD226 in the pathogenesis of systemic lupus erythematosus
    keyword : SLE, CD226, DNAM-1
    2019.04~2022.03.
  • The role of CD300a in the pathogenesis of systemic sclerosis
    keyword : CD300a, "systemic sclerosis"
    2016.04~2019.03.
Academic Activities
Papers
1. Masahiro Ayano, Hiroshi Tsukamoto, Hiroki Mitoma, yasutaka kimoto, Mitsuteru Akahoshi, Yojiro Arinobu, Toshihiro Miyamoto, Takahiko Horiuchi, Hiroaki Niiro, Koji Nagafuji, Mine Harada, Koichi Akashi, CD34-selected versus unmanipulated autologous haematopoietic stem cell transplantation in the treatment of severe systemic sclerosis: A post hoc analysis of a phase I/II clinical trial conducted in Japan, Arthritis Research and Therapy, 10.1186/s13075-019-1823-0, 21, 1, 2019.01, BACKGROUND: The effectiveness of autologous haematopoietic stem cell transplantation (auto-HSCT) in treating severe systemic sclerosis (SSc) is established; however, the necessity of purified CD34+ cell grafts and the appropriate conditioning regimen remain unclear. This study aimed to compare the efficacy and safety of CD34-selected auto-HSCT with unmanipulated auto-HSCT to treat severe SSc.

METHODS: This study was a post hoc analysis of a phase I/II clinical trial conducted in Japan. Nineteen patients with severe SSc were enrolled. Peripheral blood stem cells (PBSCs) were mobilised with cyclophosphamide (4 g/m2) and filgrastim (10 μg/kg/day). Following PBSC collection by apheresis, CD34+ cells were immunologically selected in 11 patients. All patients were treated with high-dose cyclophosphamide (200 mg/kg) monotherapy as a conditioning regimen and received CD34-selected (n = 11) or unmanipulated auto-HSCT (n = 8). Changes in skin sclerosis and pulmonary function were assessed over an 8-year follow-up period. Differences in the changes, toxicity, progression-free survival (PFS) and overall survival were compared between patients who had received CD34-selected auto-HSCT and those who had received unmanipulated auto-HSCT.

RESULTS: Skin sclerosis progressively improved after transplantation over an 8-year follow-up period in both groups, and the improvement was significantly greater in the CD34-selected group than in the unmanipulated group. Forced vital capacity in the CD34-selected group continuously increased over 8 years, whereas in the unmanipulated group it returned to baseline 3 years after transplantation. Toxicity and viral infections, such as cytomegalovirus infection and herpes zoster, were more frequently found in the CD34-selected group than in the unmanipulated group. The frequency of severe adverse events, such as bacterial infections or organ toxicity, was similar between the two groups. No treatment-related deaths occurred in either treatment group. PFS of the CD34-selected group was greater than that of the unmanipulated group, and the 5-year PFS rates of the CD34-selected and unmanipulated group were 81.8% and 50% respectively.

CONCLUSIONS: CD34-selected auto-HSCT may produce favourable effects on improvement of skin sclerosis and pulmonary function compared with unmanipulated auto-HSCT. Use of CD34-selected auto-HSCT with high-dose cyclophosphamide monotherapy as a conditioning regimen may offer an excellent benefit-to-risk balance..
2. Masahiro Ayano, Hiroshi Tsukamoto, Kentaro Kohno, Naoyasu Ueda, Atsushi Tanaka, Hiroki Mitoma, Mitsuteru Akahoshi, Yojiro Arinobu, Hiroaki Niiro, Takahiko Horiuchi, koichi akashi, Increased CD226 Expression on CD8+ T Cells Is Associated with Upregulated Cytokine Production and Endothelial Cell Injury in Patients with Systemic Sclerosis, JOURNAL OF IMMUNOLOGY, 10.4049/jimmunol.1403046, 195, 3, 892-900, 2015.08.
Educational
Other Educational Activities
  • 2016.04.